Andreas Barratt-Due

• Anthon, Carl Thomas; Pène, Frédéric; Perner, Anders; Azoulay, Elie; Puxty, Kathryn & Van De Louw, Andry [Show all 47 contributors for this article] (2024). Platelet transfusions in adult ICU patients with thrombocytopenia: A sub-study of the PLOT-ICU inception cohort study. Acta Anaesthesiologica Scandinavica. ISSN 0001-5172. doi: 10.1111/aas.14467.
• Barratt-Due, Andreas; Pettersen, Kristin; Dahl, Tuva Børresdatter; Holter, Jan Cato; Grønli, Renathe Henriksen & Dyrhol-Riise, Anne Ma [Show all 20 contributors for this article] (2024). Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients. Journal of Internal Medicine. ISSN 0954-6820. doi: 10.1111/joim.13783.
• Aslam, Tayyba Naz; Barratt-Due, Andreas; Fiane, Arnt Eltvedt; Friis, Camilla Margrethe; Hofsø, Kristin & Kåsine, Trine [Show all 8 contributors for this article] (2024). Gravide med akutt, alvorlig respirasjonssvikt utl⊘st av covid-19. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 144(1), p. 1–8. doi: 10.4045/tidsskr.23.0615.
• Ueland, Thor; Michelsen, Annika Elisabet; Tveita, Anders; Kåsine, Trine; Dahl, Tuva Børresdatter & Finbråten, Ane-Kristine [Show all 16 contributors for this article] (2023). Coagulopathy and adverse outcomes in hospitalized patients with COVID-19: results from the NOR-Solidarity trial. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 8(1). doi: 10.1016/j.rpth.2023.102289. Full text in Research Archive
• Buanes, Eirik Alnes; Bruserud, Øyvind; Carracedo Huroz, Sergio; Barratt-Due, Andreas; Flaatten, Hans Kristian & Kvåle, Reidar (2023). External validation of SAPS II score reported to the Norwegian Intensive Care and Pandemic Registry (NIPaR). Norsk Epidemiologi. ISSN 0803-2491. 31(1-2), p. 99–104. doi: 10.5324/nje.v31i1-2.5618.
• Murphy, Sarah Louise Mikalsen; Halvorsen, Bente; Holter, Jan Cato; Huse, Camilla; Tveita, Anders & Trøseid, Marius [Show all 24 contributors for this article] (2023). Circulating markers of extracellular matrix remodelling in severe COVID-19 patients. Journal of Internal Medicine. ISSN 0954-6820. 294(6), p. 784–797. doi: 10.1111/joim.13725. Full text in Research Archive
• Anthon, Carl Thomas; Pène, Frédéric; Perner, Anders; Azoulay, Elie; Puxty, Kathryn & Van De Louw, Andry [Show all 55 contributors for this article] (2023). Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU). Intensive Care Medicine. ISSN 0342-4642. 49(11), p. 1327–1338. doi: 10.1007/s00134-023-07225-2. Full text in Research Archive
• Amstutz, Alain; Speich, Benjamin; Mentré, France; Rüegg, Corina Silvia; Belhadi, Drifa & Assoumou, Lambert [Show all 35 contributors for this article] (2023). Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. The Lancet Respiratory Medicine. ISSN 2213-2600. 11(5), p. 453–464. doi: 10.1016/S2213-2600(22)00528-8.
• Cavaillon, Jean-Marc; Artigas, Antonio; Barratt-Due, Andreas; Giamarellos-Bourboulis, Evangelos J.; Gómez, Hernando & Hayem, Gilles [Show all 8 contributors for this article] (2023). SEVERE CORONAVIRUS DISEASE 2019: FROM PATHOGENESIS TO THERAPY. Shock. ISSN 1073-2322. 59(3), p. 10–15. doi: 10.1097/SHK.0000000000001956.
• Bakkehaug, Jens Petter; Kåsine, Trine; Romundstad, Luis Georg; Narum, Jon; Laake, Jon Henrik & Svalebjørg, Morten [Show all 12 contributors for this article] (2023). Ekstrakorporal membranoksygenering ved akutt lungesviktsyndrom hos covid-19-pasienter. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(2). doi: 10.4045/tidsskr.22.0545.
• Pan, Hongchao; Peto, Richard; Karim, Quarraisha Abdool; Alejandria, Marissa M.; Henao-Restrepo, Ana-Maria & Hernández-García, César [Show all 51 contributors for this article] (2022). Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. The Lancet. ISSN 0140-6736. 399(10339), p. 1941–1953. doi: 10.1016/S0140-6736(22)00519-0. Full text in Research Archive Show summary

  Background The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and interferon (IFN)-β1a were discontinued for futility but randomisation to remdesivir continued. Here, we report the final results of Solidarity and meta-analyses of mortality in all relevant trials to date. Methods Solidarity enrolled consenting adults (aged ≥18 years) recently hospitalised with, in the view of their doctor, definite COVID-19 and no contraindication to any of the study drugs, regardless of any other patient characteristics. Participants were randomly allocated, in equal proportions between the locally available options, to receive whichever of the four study drugs (lopinavir, hydroxychloroquine, IFN-β1a, or remdesivir) were locally available at that time or no study drug (controls). All patients also received the local standard of care. No placebos were given. The protocol-specified primary endpoint was in-hospital mortality, subdivided by disease severity. Secondary endpoints were progression to ventilation if not already ventilated, and time-to-discharge from hospital. Final log-rank and Kaplan-Meier analyses are presented for remdesivir, and are appended for all four study drugs. Meta-analyses give weighted averages of the mortality findings in this and all other randomised trials of these drugs among hospital inpatients. Solidarity is registered with ISRCTN, ISRCTN83971151, and ClinicalTrials.gov, NCT04315948. Findings Between March 22, 2020, and Jan 29, 2021, 14 304 potentially eligible patients were recruited from 454 hospitals in 35 countries in all six WHO regions. After the exclusion of 83 (0·6%) patients with a refuted COVID-19 diagnosis or encrypted consent not entered into the database, Solidarity enrolled 14 221 patients, including 8275 randomly allocated (1:1) either to remdesivir (ten daily infusions, unless discharged earlier) or to its control (allocated no study drug although remdesivir was locally available). Compliance was high in both groups. Overall, 602 (14·5%) of 4146 patients assigned to remdesivir died versus 643 (15·6%) of 4129 assigned to control (mortality rate ratio [RR] 0·91 [95% CI 0·82–1·02], p=0·12). Of those already ventilated, 151 (42·1%) of 359 assigned to remdesivir died versus 134 (38·6%) of 347 assigned to control (RR 1·13 [0·89–1·42], p=0·32). Of those not ventilated but on oxygen, 14·6% assigned to remdesivir died versus 16·3% assigned to control (RR 0·87 [0·76–0·99], p=0·03). Of 1730 not on oxygen initially, 2·9% assigned to remdesivir died versus 3·8% assigned to control (RR 0·76 [0·46–1·28], p=0·30). Combining all those not ventilated initially, 11·9% assigned to remdesivir died versus 13·5% assigned to control (RR 0·86 [0·76–0·98], p=0·02) and 14·1% versus 15·7% progressed to ventilation (RR 0·88 [0·77–1·00], p=0·04). The non-prespecified composite outcome of death or progression to ventilation occurred in 19·6% assigned to remdesivir versus 22·5% assigned to control (RR 0·84 [0·75–0·93], p=0·001). Allocation to daily remdesivir infusions (vs open-label control) delayed discharge by about 1 day during the 10-day treatment period. A meta-analysis of mortality in all randomised trials of remdesivir versus no remdesivir yielded similar findings. Interpretation Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. Among other hospitalised patients, it has a small effect against death or progression to ventilation (or both).

• Tran, Trung; Vaage, Eline Benno; Mehta, Adi; Chopra, Adity; Tietze, Lisa & Kolderup, Heidi Anette [Show all 40 contributors for this article] (2022). Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. npj Vaccines. ISSN 2059-0105. 7(1). doi: 10.1038/s41541-022-00586-7. Full text in Research Archive
• Burghi, Gaston; Metaxa, Victoria; Pickkers, Peter; Soares, Marcio; Rello, Jordi & Bauer, Philippe R. [Show all 20 contributors for this article] (2022). End of life decisions in immunocompromised patients with acute respiratory failure. Journal of critical care. ISSN 0883-9441. 72. doi: 10.1016/j.jcrc.2022.154152.
• Tveita, Anders Aune; Murphy, Sarah Louise Mikalsen; Holter, Jan Cato; Kildal, Anders Benjamin; Michelsen, Annika Elisabet & Lerum, Tøri Vigeland [Show all 28 contributors for this article] (2022). High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19. Journal of Infectious Diseases. ISSN 0022-1899. 226(12), p. 2150–2160. doi: 10.1093/infdis/jiac313. Full text in Research Archive
• Trøseid, Marius; Dahl, Tuva Børresdatter; Holter, Jan Cato; Kildal, Anders Benjamin; Murphy, Sarah Louise Mikalsen & Yang, Kuan [Show all 28 contributors for this article] (2022). Persistent T-cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: Results from two Norwegian cohort studies. Journal of Internal Medicine. ISSN 0954-6820. 292(5), p. 816–828. doi: 10.1111/joim.13549. Full text in Research Archive
• Søvik, Signe; Barratt-Due, Andreas; Kåsine, Trine; Olasveengen, Theresa M.; Strand, Marianne Wigernes & Tveita, Anders Aune [Show all 16 contributors for this article] (2022). Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation. Journal of Infection. ISSN 0163-4453. 85(1), p. 57–63. doi: 10.1016/j.jinf.2022.05.015. Full text in Research Archive
• Ueland, Thor; Sørvoll, Ingvild Hausberg; Mørtberg, Trude Victoria; Dahl, Tuva Børresdatter; Lerum, Tøri Vigeland & Michelsen, Annika Elisabet [Show all 16 contributors for this article] (2022). Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. Platelets. ISSN 0953-7104. 33(4), p. 640–644. doi: 10.1080/09537104.2022.2042238. Full text in Research Archive
• Vestad, Beate; Ueland, Thor; Lerum, Tøri Vigeland; Dahl, Tuva Børresdatter; Holm, Kristian & Barratt-Due, Andreas [Show all 37 contributors for this article] (2022). Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations. Journal of Internal Medicine. ISSN 0954-6820. 291(6), p. 801–812. doi: 10.1111/joim.13458. Full text in Research Archive Show summary

  Background: Although coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, mounting evidence suggests that the gastrointestinal (GI) tract is involved in the disease, with gut barrier dysfunction and gut microbiota alterations being related to disease severity. Whether these alterations persist and are related to long-term respiratory dysfunction remains unknown. Methods: Plasma was collected during hospital admission and after three months from the NOR-Solidarity trial (n = 181) and analysed for markers of gut barrier dysfunction and inflammation. At the three-month follow-up, pulmonary function was assessed by measuring the diffusing capacity of the lungs for carbon monoxide (DLCO ). Rectal swabs for gut microbiota analyses were collected (n = 97) and analysed by sequencing the 16S rRNA gene. Results: Gut microbiota diversity was reduced in COVID-19 patients with respiratory dysfunction, defined as DLCO below the lower limit of normal three months after hospitalisation. These patients also had an altered global gut microbiota composition, with reduced relative abundance of 20 bacterial taxa and increased abundance of five taxa, including Veillonella, potentially linked to fibrosis. During hospitalisation, increased plasma levels of lipopolysaccharide-binding protein (LBP) were strongly associated with respiratory failure, defined as pO2 /fiO2 -(P/F ratio)

• Lerum, Tøri Vigeland; Barratt-Due, Andreas; Aaløkken, Trond Mogens; Skjønsberg, Ole Henning; SOLIDARITY consortium, NOR- & Hoff, Dag Arne Lihaug (2021). Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. Scientific Reports. ISSN 2045-2322. doi: 10.1038/s41598-021-02547-x.
• Coelho Medeiros, Pedro Miguel; Schjalm, Camilla; Christiansen, Dorte; Sokolova, Marina; Pischke, Soeren Erik & Würzner, Reinhard [Show all 8 contributors for this article] (2021). Vitamin C, Hydrocortisone, and the Combination Thereof Significantly Inhibited Two of Nine Inflammatory Markers Induced by Escherichia Coli But Not by Staphylococcus Aureus - When Incubated in Human Whole Blood. Shock. ISSN 1073-2322. 57(1), p. 72–80. doi: 10.1097/SHK.0000000000001834. Full text in Research Archive
• Thomas, Anub Mathew; Chaban, Viktoriia; Pischke, Soeren; Orrem, Hilde Lang; Bosnes, Vidar & Sunde, Kjetil [Show all 13 contributors for this article] (2021). Complement ratios C3bc/C3 and sC5b-9/C5 do not increase the sensitivity of detecting acute complement activation systemically. Molecular Immunology. ISSN 0161-5890. 141, p. 273–279. doi: 10.1016/j.molimm.2021.11.016. Full text in Research Archive
• Blaise Pascal, Furaha Nzanzu; Malisawa, Agnes; Barratt-Due, Andreas; Namboya, Felix & Pollach, Gregor (2021). General anaesthesia related mortality in a limited resource settings region: a retrospective study in two teaching hospitals of Butembo. BMC Anesthesiology. ISSN 1471-2253. 21(1). doi: 10.1186/s12871-021-01280-2.
• Kåsine, Trine; Riise, Anne Margarita Dyrhol; Barratt-Due, Andreas; Kildal, Anders Benjamin; Olsen, Inge Christoffer & Nezvalova-Henriksen, Katerina [Show all 39 contributors for this article] (2021). Neutrophil count predicts outcome in hospitalized COVID-19 patients. Results from the NOR-Solidarity trial. Journal of Internal Medicine. ISSN 0954-6820. 291(2), p. 241–243. doi: 10.1111/joim.13377. Show summary

  Despite numerous studies on SARS-CoV-2-induced inflammation, we still lack markers for rapid disease progression with admission to intensive care unit (ICU) or respiratory failure(RF). Few studies have evaluated the prognostic value of routine diagnostic repertoire available at most hospitals. The NOR-Solidarity trial is an independent add-on study to the WHO Solidarity trial, evaluating hydroxychloroquine (HCQ)and remdesivir compared to standard of care in hospitalized COVID-19 patients [1]. We explored whether standard biomarkers in peripheral blood could give information on ICU admission and RFin hospitalized COVID-19 patients.

• Tangen, Jorun; Aukrust, Pål; Barratt-Due, Andreas; Skulstad, Helge & Edvardsen, Thor (2021). Reduced cardiac function by echocardiography in a minority of COVID-19 patients three months after hospitalization. Journal of the American Society of Echocardiography. ISSN 0894-7317. doi: 10.1016/j.echo.2021.10.014. Full text in Research Archive
• Diallo, Alpha; Trøseid, Marius; Simensen, Victoria C; Boston, Anaïs; Demotes, Jacques & Olsen, Inge Christoffer [Show all 28 contributors for this article] (2021). Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clinical Microbiology and Infection (CMI). ISSN 1198-743X. 28(1), p. 1–6. doi: 10.1016/j.cmi.2021.10.011.
• Lerum, Tøri Vigeland; Maltzahn, Niklas; Aukrust, Pål; Trøseid, Marius; Nezvalova-Henriksen, Katerina & Kåsine, Trine [Show all 27 contributors for this article] (2021). Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. Scientific Reports. ISSN 2045-2322. 11, p. 1–12. doi: 10.1038/s41598-021-02547-x. Full text in Research Archive Show summary

  The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DLCO), and chest-CT were performed at 23 Norwegian hospitals included in the NOR-SOLIDARITY trial, an open-labelled, randomised clinical trial, investigating the efficacy of remdesivir and hydroxychloroquine (HCQ). Thirty-eight percent had a CAT-score ≥ 10. DLCO was below the lower limit of normal in 29.6%. Ground-glass opacities were present in 39.8% on chest-CT, parenchymal bands were found in 41.7%. At admission, low pO2/FiO2 ratio, ICU treatment, high viral load, and low antibody levels, were predictors of a poorer pulmonary outcome after 3 months. High levels of matrix metalloproteinase (MMP)-9 during hospitalisation and at 3 months were associated with persistent CT-findings. Except for a negative effect of remdesivir on CAT-score, we found no effect of remdesivir or HCQ on long-term pulmonary outcomes. Three months after hospital admission for COVID-19, a high prevalence of respiratory symptoms, reduced DLCO, and persistent CT-findings was observed. Low pO2/FiO2 ratio, ICU-admission, high viral load, low antibody levels, and high levels of MMP-9 were associated with a worse pulmonary outcome.

• van de Louw, Andry; Rello, Jordi; Martin-Loeches, Ignacio; Mokart, Djamel; Metaxa, Victoria & Benoit, Dominique D. [Show all 19 contributors for this article] (2021). Bacteremia in critically ill immunocompromised patients with acute hypoxic respiratory failure: A post-hoc analysis of a prospective multicenter multinational cohort. Journal of critical care. ISSN 0883-9441. 64, p. 114–119. doi: 10.1016/j.jcrc.2021.03.014.
• Barratt-Due, Andreas; Olsen, Inge Christoffer; Nezvalova-Henriksen, Katerina; Kåsine, Trine; Lund-Johansen, Fridtjof & Hoel, Hedda Benedicte [Show all 43 contributors for this article] (2021). Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial. Annals of Internal Medicine. ISSN 0003-4819. 174(9), p. 1261–1269. doi: 10.7326/M21-0653. Full text in Research Archive Show summary

  Background: New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the antiviral effects of these drugs are not known. Objective: To evaluate the effects of remdesivir and HCQ on all-cause, in-hospital mortality; the degree of respiratory failure and inflammation; and viral clearance in the oropharynx. Design: NOR-Solidarity is an independent, add-on, randomized controlled trial to the WHO Solidarity trial that included biobanking and 3 months of clinical follow-up (ClinicalTrials.gov: NCT04321616). Setting: 23 hospitals in Norway. Patients: Eligible patients were adults hospitalized with confirmed SARS-CoV-2 infection. Intervention: Between 28 March and 4 October 2020, a total of 185 patients were randomly assigned and 181 were included in the full analysis set. Patients received remdesivir (n = 42), HCQ (n = 52), or standard of care (SoC) (n = 87). Measurements: In addition to the primary end point of WHO Solidarity, study-specific outcomes were viral clearance in oropharyngeal specimens, the degree of respiratory failure, and inflammatory variables. Results: No significant differences were seen between treatment groups in mortality during hospitalization. There was a marked decrease in SARS-CoV-2 load in the oropharynx during the first week overall, with similar decreases and 10-day viral loads among the remdesivir, HCQ, and SoC groups. Remdesivir and HCQ did not affect the degree of respiratory failure or inflammatory variables in plasma or serum. The lack of antiviral effect was not associated with symptom duration, level of viral load, degree of inflammation, or presence of antibodies against SARS-CoV-2 at hospital admittance. Limitation: The trial had no placebo group. Conclusion: Neither remdesivir nor HCQ affected viral clearance in hospitalized patients with COVID-19.

• Aamodt, Anne Hege; Høgestøl, Einar August; Popperud, Trine Haug; Holter, Jan Cato; Dyrhol-Riise, Anne Ma & Tonby, Kristian [Show all 15 contributors for this article] (2021). Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. Journal of Neurology. ISSN 0340-5354. doi: 10.1007/s00415-021-10517-6. Full text in Research Archive
• Bjørkto, Magnus Holter; Barratt-Due, Andreas; Nordøy, Ingvild; Dörje, Christina; Galteland, Eivind & Lind, Andreas [Show all 9 contributors for this article] (2021). The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report. BMC Infectious Diseases. ISSN 1471-2334. 21:137, p. 1–6. doi: 10.1186/s12879-021-05789-2.
• Munshi, Laveena; Darmon, Michael; Soares, Marcio; Pickkers, Peter; Bauer, Philippe R. & Meert, Anne-Pascale [Show all 18 contributors for this article] (2020). Acute Respiratory Failure Outcomes in Patients with Hematologic Malignancies and Hematopoietic Cell Transplant: A Secondary Analysis of the EFRAIM Study. Biology of Blood and Marrow Transplantation. ISSN 1083-8791. doi: 10.1016/j.bbmt.2020.09.035. Show summary

  Patients with allogeneic hematopoietic cell transplantation (HCT) who develop acute respiratory failure (ARF) are perceived to have worse outcomes than autologous HCT recipients and non-transplant patients with hematologic malignancy (HM). Within a large international prospective cohort, we evaluated clinical outcomes in these 3 populations. We conducted a secondary analysis of the EFRAIM study, a multicenter observational study of immunocompromised adults with ARF admitted to 62 intensive care units (ICUs) in 16 countries. We described characteristics and compared outcomes of patients with HM who did not undergo transplantation and patients who underwent autologous or allogeneic HCT using multivariable logistic regression and propensity score-matched analyses. A total of 801 patients were included: 570 who did not undergo transplantation, 86 autologous HCT recipients and 145 allogeneic HCT recipients. Acute myelogenous leukemia (171 of 570; 30%) was the most common HM and most common indication for allogeneic HCT (76 of 145; 52%). Compared with the patients who did not undergo HCT and autologous HCT recipients, allogeneic HCT recipients were younger, had fewer comorbid conditions, and were more likely to undergo diagnostic bronchoscopy in the ICU. Unadjusted ICU and hospital mortality were 35% and 45%, respectively, across the entire cohort. In multivariable regression analysis, autologous HCT (odds ratio [OR], 1.07; 95% confidence interval [CI], .57 to 2.03; P = .82) and allogeneic HCT (OR, .99; 95% CI, .60 to 1.66; P = .98) were not associated with higher hospital mortality compared with the no-HCT cohort, adjusting for demographic, functional, clinical, malignancy, and ARF characteristics. The results were similar when analyzed using propensity score-matching techniques. Our findings indicate that autologous and allogeneic HCT recipients who develop ARF and require ICU admission have similar hospital mortality as patients with HM not treated with HCT.

• Demoule, Alexandre; Antonelli, Massimo; Schellongowski, Peter; Pickkers, Peter; Soares, Marcio & Meyhoff, Tine Sylvest [Show all 25 contributors for this article] (2020). Respiratory Mechanics and Outcomes in Immunocompromised Patients With ARDS: A Secondary Analysis of the EFRAIM Study. Chest. ISSN 0012-3692. 158(5), p. 1947–1957. doi: 10.1016/j.chest.2020.05.602.
• Pan, Hongchao; Peto, Richard; Henao-Restrepo, Ana Maria; Preziosi, Marie-Pierre; Sathiyamoorthy, Vasee & Karim, Quarraisha Abdool [Show all 74 contributors for this article] (2020). Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. New England Journal of Medicine. ISSN 0028-4793. 384(6), p. 497–511. doi: 10.1056/NEJMoa2023184.
• Blaise Pascal, Furaha Nzanzu; Musavuli, Paulin Kambale; Ketha, Joel Kambale; Sikakulya, Franck Katembo; Barratt-Due, Andreas & Castner, Thomas [Show all 7 contributors for this article] (2020). Practice of standard monitoring during anaesthesia in hospitals of North Kivu: A survey of health facilities of the health antenna of Butembo. BMC Health Services Research. ISSN 1472-6963. 20:262, p. 1–8. doi: 10.1186/s12913-020-05076-x.
• Kayambankadzanja, Raphael Kazidule; Lihaka, Moses; Barratt-Due, Andreas; Kachingwe, Mtisunge; Kumwenda, Wezzie & Lester, Rebecca [Show all 9 contributors for this article] (2020). The use of antibiotics in the intensive care unit of a tertiary hospital in Malawi. BMC Infectious Diseases. ISSN 1471-2334. 20(1), p. 1–7. doi: 10.1186/s12879-020-05505-6.
• Messika, Jonathan; Darmon, Michael; Mal, Hervé; Pickkers, Peter; Soares, Marcio & Canet, Emmanuel [Show all 30 contributors for this article] (2020). Etiologies and Outcomes of Acute Respiratory Failure in Solid Organ Transplant Recipients: Insight Into the EFRAIM Multicenter Cohort. Transplantation Proceedings. ISSN 0041-1345. 52(10), p. 2980–2987. doi: 10.1016/j.transproceed.2020.02.170.
• Pischke, Soeren; Hødnebø, Stina; Wester, Torjus; Haugaa, Håkon; Kvernebo, Knut & Barratt-Due, Andreas [Show all 7 contributors for this article] (2020). Intraperitoneal microdialysis detects intestinal leakage earlier than hemodynamic surveillance and systemic inflammation in a pig model. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 56(2), p. 219–227. doi: 10.1080/00365521.2020.1863459. Full text in Research Archive
• Aamodt, Anne Hege; Harbo, Hanne Flinstad; Eldøen, Guttorm; Barratt-Due, Andreas & Aukrust, Pål (2020). Hvordan påvirkes hjernen ved covid-19? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 140(10), p. 968–969. doi: 10.4045/tidsskr.20.0444.
• Mokart, Djamel; Darmon, Michael; Schellongowski, Peter; Pickkers, Peter; Soares, Marcio & Rello, Jordi [Show all 28 contributors for this article] (2020). Acute respiratory failure in immunocompromised patients: outcome and clinical features according to neutropenia status. Annals of Intensive Care. ISSN 2110-5820. 10:146, p. 1–9. doi: 10.1186/s13613-020-00764-7.
• Ueland, Thor; Heggelund, Lars; Lind, Andreas; Holten, Aleksander Rygh; Tonby, Kristian & Michelsen, Annika [Show all 26 contributors for this article] (2020). Elevated plasma sTIM-3 levels in patients with severe COVID-19. Journal of Allergy and Clinical Immunology. ISSN 0091-6749. 147(1), p. 92–98. doi: 10.1016/j.jaci.2020.09.007. Full text in Research Archive
• Holter, Jan Cato; Pischke, Soeren; de Boer, Eline; Lind, Andreas; Jenum, Synne & Holten, Aleksander Rygh [Show all 32 contributors for this article] (2020). Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients . Proceedings of the National Academy of Sciences of the United States of America. ISSN 0027-8424. 117(40), p. 25018–25025. doi: 10.1073/pnas.2010540117. Full text in Research Archive
• Azoulay, Elie; Bauer, Philippe R.; Mariotte, Eric; Russell, Lene; Knoebl, Paul & Martín-Loeches, Ignacio [Show all 20 contributors for this article] (2019). Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Medicine. ISSN 0342-4642. 45(11), p. 1518–1539. doi: 10.1007/s00134-019-05736-5.
• Bauer, Philippe R.; Chevret, Sylvie; Yadav, Hemang; Mehta, Sangeeta; Pickkers, Peter & Bukan, Ramin Brandt [Show all 35 contributors for this article] (2019). Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy. European Respiratory Journal. ISSN 0903-1936. 54:1802442, p. 1–11. doi: 10.1183/13993003.02442-2018.
• Thomas, Anub Mathew; Gerogianni, Alexandra; McAdam, Martin Berner; Fløisand, Yngvar; Lau, Corinna & Espevik, Terje [Show all 9 contributors for this article] (2019). Complement component C5 and TLR molecule CD14 mediate heme-induced thromboinflammation in human blood. Journal of Immunology. ISSN 0022-1767. 203(6), p. 1571–1578. doi: 10.4049/jimmunol.1900047. Full text in Research Archive
• Thorgersen, Ebbe Billmann; Barratt-Due, Andreas; Haugaa, Håkon; Harboe, Morten; Pischke, Søren & Nilsson, Per [Show all 7 contributors for this article] (2019). The role of complement in liver injury, regeneration, and transplantation. Hepatology. ISSN 0270-9139. 70(2), p. 725–736. doi: 10.1002/hep.30508. Full text in Research Archive
• Martin-Loeches, Ignacio; Lemiale, Virginie; Geoghegan, Pierce; McMahon, Mary Aisling; Pickkers, Peter & Soares, Marcio [Show all 40 contributors for this article] (2019). Influenza and associated co-infections in critically ill immunosuppressed patients. Critical Care. ISSN 1364-8535. 23:152, p. 1–10. doi: 10.1186/s13054-019-2425-6. Full text in Research Archive
• Orrem, Hilde Lang; Nilsson, Per; Pischke, Søren Erik; Grindheim, Guro; Garred, Peter & Seljeflot, Ingebjørg [Show all 12 contributors for this article] (2018). Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock. ESC Heart Failure. ISSN 2055-5822. 5(3), p. 292–301. doi: 10.1002/ehf2.12266. Full text in Research Archive
• Orrem, Hilde Lang; Nilsson, Per; Pischke, Søren Erik; Kleveland, Ola; Yndestad, Arne & Ekholt, Karin [Show all 18 contributors for this article] (2018). IL-6 receptor inhibition by tocilizumab attenuated expression of C5a receptor 1 and 2 in non-ST-elevation myocardial infarction. Frontiers in Immunology. ISSN 1664-3224. 9. doi: 10.3389/fimmu.2018.02035. Full text in Research Archive
• Thomas, Anub Mathew; Schjalm, Camilla; Nilsson, Per; Lindenskov, Paal Helge H.; Rørtveit, Runa & Solberg, Rønnaug [Show all 15 contributors for this article] (2018). Combined Inhibition of C5 and CD14 Attenuates Systemic Inflammation in a Piglet Model of Meconium Aspiration Syndrome. Neonatology. ISSN 1661-7800. 113(4), p. 322–330. doi: 10.1159/000486542. Full text in Research Archive
• Azoulay, Elie; Pickkers, Peter; Soares, Marcio; Perner, Anders; Rello, Jordi & Bauer, Philippe R. [Show all 37 contributors for this article] (2017). Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Medicine. ISSN 0342-4642. 43(12), p. 1808–1819. doi: 10.1007/s00134-017-4947-1.
• Hellerud, Bernt C; Orrem, Hilde Lang; Dybwik, Knut Gustav; Pischke, Søren Erik; Barratt-Due, Andreas & Castellheim, Albert [Show all 15 contributors for this article] (2017). Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsis. Journal of Intensive Care. ISSN 2052-0492. 5:21, p. 1–9. doi: 10.1186/s40560-017-0217-0. Full text in Research Archive
• Nilsson, Per; Thomas, Anub Mathew; Bergseth, Grete; Gustavsen, Alice; Volokhina, Elena B. & van den Heuvel, Lambertus P. [Show all 8 contributors for this article] (2017). Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses. Molecular Immunology. ISSN 0161-5890. 89, p. 111–114. doi: 10.1016/j.molimm.2017.05.021. Full text in Research Archive
• Ricklin, Daniel; Barratt-Due, Andreas & Mollnes, Tom Eirik (2017). Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Molecular Immunology. ISSN 0161-5890. 89, p. 10–21. doi: 10.1016/j.molimm.2017.05.013. Full text in Research Archive
• Gustavsen, Alice; Skattum, Lillemor; Bergseth, Grete; Lorentzen, Bjørg; Fløisand, Yngvar & Bosnes, Vidar [Show all 8 contributors for this article] (2017). Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome. Medicine. ISSN 0025-7974. 96(11). doi: 10.1097/MD.0000000000006338. Full text in Research Archive
• Pischke, Søren Erik; Gustavsen, Alice; Orrem, Hilde Lang; Egge, Kjetil Hagene; Courivaud, Fredric A A & Fontenelle, Hugues [Show all 15 contributors for this article] (2017). Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function. Basic Research in Cardiology. ISSN 0300-8428. 112:20(3). doi: 10.1007/s00395-017-0610-9. Full text in Research Archive
• Barratt-Due, Andreas; Pischke, Søren Erik; Nilsson, Per; Espevik, Terje & Mollnes, Tom Eirik (2017). Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets. Journal of Leukocyte Biology. ISSN 0741-5400. 101(1), p. 193–204. doi: 10.1189/jlb.3VMR0316-132R. Full text in Research Archive
• Barratt-Due, Andreas; Fløisand, Yngvar; Lang, Hilde Elisabeth; Kvam, Ann Kristin; Holme, Pål Andre & Bergseth, Grete [Show all 8 contributors for this article] (2016). Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. ISSN 1462-0324. doi: 10.1093/rheumatology/kew040. Full text in Research Archive
• Skjeflo, Espen Waage; Sagatun, Caroline; Dybwik, Knut; Aam, Sturla; Urving, Sven Haakon & Nunn, Miles A. [Show all 14 contributors for this article] (2015). Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis. Critical Care. ISSN 1364-8535. 19:415. doi: 10.1186/s13054-015-1129-9. Full text in Research Archive
• Egge, Kjetil Hagene; Barratt-Due, Andreas; Nymo, Stig Haugset; Lindstad, Julie Katrine; Pharo, Anne Margrethe & Lau, Corinna [Show all 9 contributors for this article] (2015). The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clinical and Experimental Immunology. ISSN 0009-9104. 181(3), p. 457–467. doi: 10.1111/cei.12645.
• Egge, Kjetil Hagene; Thorgersen, Ebbe Billmann; Pischke, Søren Erik; Lindstad, Julie Katrine; Pharo, Anne Margrethe & Bongoni, Anjan K. [Show all 10 contributors for this article] (2015). Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. Immunobiology. ISSN 0171-2985. 220(8), p. 999–1005. doi: 10.1016/j.imbio.2015.04.002.
• Jensen, L.L.; Barratt-Due, Andreas; Englund, P.N.; Harju, Jarkko A.; Sigursson, Theodor Skuli & Liberg, John-Petter (2015). Paediatric ventilation treatment of acute lung injury in Nordic intensive care units. Acta Anaesthesiologica Scandinavica. ISSN 0001-5172. 59(5), p. 568–575. doi: 10.1111/aas.12500.
• Huber-Lang, Markus; Barratt-Due, Andreas; Pischke, Søren Erik; Sandanger, Øystein; Nilsson, Per & Nunn, Miles A. [Show all 10 contributors for this article] (2014). Double blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice. Journal of Immunology. ISSN 0022-1767. 192(11), p. 5324–5331. doi: 10.4049/jimmunol.1400341. Show summary

  Sepsis and septic shock, caused by an excessive systemic host-inflammatory response, are associated with high morbidity and mortality. The complement system and TLRs provide important pattern recognition receptors initiating the cytokine storm by extensive cross-talk. We hypothesized that double blockade of complement C5 and the TLR coreceptor CD14 could improve survival of experimental polymicrobial sepsis. Mice undergoing cecal ligation and puncture (CLP)–induced sepsis were treated with neutralizing anti-CD14 Ab biG 53, complement C5 inhibitor coversin (Ornithodoros moubata C inhibitor), or a combination thereof. The inflammatory study (24-h observation) revealed statistically significant increases in 22 of 24 measured plasma biomarkers in the untreated CLP group, comprising 14 pro- and anti-inflammatory cytokines and 8 chemokines, growth factors, and granulocyte activation markers. Single CD14 or C5 blockade significantly inhibited 20 and 19 of the 22 biomarkers, respectively. Combined CD14 and C5 inhibition significantly reduced all 22 biomarkers (mean reduction 85%; range 54–95%) compared with the untreated CLP group. Double blockade was more potent than single treatment and was required to significantly inhibit IL-6 and CXCL1. Combined inhibition significantly reduced morbidity (motility and eyelid movement) and mortality measured over 10 d. In the positive control CLP group, median survival was 36 h (range 24–48 h). Combined treatment increased median survival to 96 h (range 24–240 h) (p = 0.001), whereas survival in the single-treatment groups was not significantly increased (median and range for anti-CD14 and anti-C5 treatment were 36 h [24–48 h] and 48 h [24–96 h]). Combined with standard intervention therapy, specific blockade of CD14 and C5 might represent a promising new therapeutic strategy for treatment of polymicrobial sepsis.

• Egge, Kjetil Hagene; Thorgersen, Ebbe Billmann; Lindstad, Julie Katrine; Pharo, Anne Margrethe; Lambris, John D. & Barratt-Due, Andreas [Show all 7 contributors for this article] (2014). Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood. Innate Immunity. ISSN 1753-4259. 20(1), p. 68–77. doi: 10.1177/1753425913482993.
• Barratt-Due, Andreas; Thorgersen, Ebbe Billmann; Egge, Kjetil Hagene; Pischke, Søren Erik; Sokolov, Andrey & Hellerud, Bernt C [Show all 13 contributors for this article] (2013). Combined Inhibition of Complement (C5) and CD14 Markedly Attenuates Inflammation, Thrombogenicity, and Hemodynamic Changes in Porcine Sepsis. Journal of Immunology. ISSN 0022-1767. 191(2), p. 819–827. doi: 10.4049/jimmunol.1201909.
• Thorgersen, Ebbe Billmann; Pischke, Søren Erik; Barratt-Due, Andreas; Fure, Hilde; Lindstad, Julie Katrine & Pharo, Anne Margrethe [Show all 8 contributors for this article] (2013). Systemic CD14 inhibition attenuates organ inflammation in porcine escherichia coli sepsis. Infection and Immunity. ISSN 0019-9567. 81(9), p. 3173–3181. doi: 10.1128/IAI.00390-13.
• Lau, Corinna; Gunnarsen, Kristin Støen; Høydahl, Lene Støkken; Andersen, Jan Terje; Berntzen, Gøril & Pharo, Anne Margrethe [Show all 15 contributors for this article] (2013). Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation. Journal of Immunology. ISSN 0022-1767. 191(9), p. 4769–4777. doi: 10.4049/jimmunol.1301653. Full text in Research Archive
• Barratt-Due, Andreas; Sokolov, Andrey; Gustavsen, Alice; Hellerud, Bernt C; Egge, Kjetil Hagene & Pischke, Søren Erik [Show all 11 contributors for this article] (2013). Polyvalent immunoglobulin significantly attenuated the formation of IL-1 beta in Escherichia coli-induced sepsis in pigs. Immunobiology. ISSN 0171-2985. 218(5), p. 683–689. doi: 10.1016/j.imbio.2012.08.268.
• Barratt-Due, Andreas; Pischke, Søren Erik; Brekke, Ole Lars; Thorgersen, Ebbe Billmann; Nielsen, Erik Waage & Espevik, Terje [Show all 8 contributors for this article] (2012). Bride and groom in systemic inflammation - The bells ring for complement and Toll in cooperation. Immunobiology. ISSN 0171-2985. 217(11), p. 1047–1056. doi: 10.1016/j.imbio.2012.07.019.
• Barratt-Due, Andreas; Thorgersen, Ebbe Billmann; Lindstad, Julie Katrine; Pharo, Anne Margrethe; Lissina, Olga & Lambris, John D. [Show all 8 contributors for this article] (2011). Ornithodoros moubata Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans. Journal of Immunology. ISSN 0022-1767. 187(9), p. 4913–4919. doi: 10.4049/jimmunol.1101000.
• Wester, Torjus; Häggblad, Erik; Ahmed, Zaheer; Barratt-Due, Andreas; Kvernebo, Mari Skylstad & Halvorsen, Per Steinar [Show all 8 contributors for this article] (2011). Assessments of skin and tongue microcirculation reveals major changes in porcine sepsis. Clinical Physiology and Functional Imaging. ISSN 1475-0961. 31(2), p. 151–158. doi: 10.1111/j.1475-097X.2010.00994.x.
• Barratt-Due, Andreas; Johansen, Harald Thidemann; Sokolov, Andrey; Thorgersen, Ebbe Billmann; Hellerud, Bernt C & Reubsaet, Leon [Show all 13 contributors for this article] (2011). The Role of Bradykinin and the Effect of the Bradykinin Receptor Antagonist Icatibant in Porcine Sepsis. Shock. ISSN 1073-2322. 36(5), p. 517–523. doi: 10.1097/SHK.0b013e3182336a34.
• Wester, Torjus; Häggblad, Erik; Ahmed, Zaheer; Barratt-Due, Andreas; Kvernebo, Mari Skylstad & Halvorsen, Per Steinar [Show all 8 contributors for this article] (2010). Assessments of skin and tongue microcirculation reveals major changes in porcine sepsis. Clinical Physiology and Functional Imaging. ISSN 1475-0961. doi: 10.1111/j.1475-097X.2010.00994.x..
• Barratt-Due, Andreas; Thorgersen, Ebbe Billmann; Lindstad, Julie Katrine; Pharo, Anne Margrethe; Brekke, Ole Lars & Christiansen, Dorte [Show all 8 contributors for this article] (2010). Selective inhibition of TNF-alpha or IL-1 beta does not affect E. coli-induced inflammation in human whole blood. Molecular Immunology. ISSN 0161-5890. 47(9), p. 1774–1782. doi: 10.1016/j.molimm.2010.02.026.
• Thorgersen, Ebbe Billmann; Hellerud, Bernt C; Nielsen, Erik Waage; Barratt-Due, Andreas; Fure, Hilde & Lindstad, Julie Katrine [Show all 12 contributors for this article] (2010). CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. The FASEB Journal. ISSN 0892-6638. 24(3), p. 712–722. doi: 10.1096/fj.09-140798.

View all works in Cristin

• Anthon, Carl Thomas; Pène, Frédéric; Perner, Anders; Azoulay, Elie; Puxty, Kathryn & Van De Louw, Andry [Show all 121 contributors for this article] (2023). Correction: Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU) (Intensive Care Medicine, (2023), 49, 11, (1327-1338), 10.1007/s00134-023-07225-2). Intensive Care Medicine. ISSN 0342-4642. doi: 10.1007/s00134-023-07291-6.
• Laake, Jon Henrik; Aslam, Tayyba Naz; Barratt-Due, Andreas; Löwhagen, Bjørn; Pischke, Soeren & Tønnessen, Tor Inge [Show all 8 contributors for this article] (2023). ARDS eller akutt lungesviktsyndrom? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(10). doi: 10.4045/tidsskr.23.0402.
• Tran, Trung; Vaage, Eline Benno; Mehta, Adi; Chopra, Adity; Tietze, Lisa & Kolderup, Heidi Anette [Show all 40 contributors for this article] (2023). Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants (npj Vaccines, (2022), 7, 1, (174), 10.1038/s41541-022-00586-7). npj Vaccines. ISSN 2059-0105. 8(1). doi: 10.1038/s41541-023-00600-6.
• Gregersen, Ida; Ueland, Thor; Holter, Jan Cato; Olsen, Maria Belland; Michelsen, Annika Elisabet & Murphy, Sarah L [Show all 22 contributors for this article] (2022). CXCL16 associates with adverse outcome and cardiac involvement in hospitalized patients with Covid-19. Journal of Infection. ISSN 0163-4453. 85(6), p. 735–738. doi: 10.1016/j.jinf.2022.09.029.
• Murphy, Sarah Louise Mikalsen; Halvorsen, Bente; Barratt-Due, Andreas; Dyrhol-Riise, Anne Ma; Aukrust, Pål & Trøseid, Marius [Show all 7 contributors for this article] (2022). Remdesivir modifies interferon response in hospitalized COVID-19 patients. Journal of Infection. ISSN 0163-4453. 85(5), p. 573–607. doi: 10.1016/j.jinf.2022.07.021.
• Anthon, Carl Thomas; Pène, Frédéric; Perner, Anders; Azoulay, Elie; Puxty, Kathryn & Van De Louw, Andry [Show all 19 contributors for this article] (2022). Platelet transfusions and thrombocytopenia in intensive care units: Protocol for an international inception cohort study (PLOT-ICU). Acta Anaesthesiologica Scandinavica. ISSN 0001-5172. 66(9), p. 1146–1155. doi: 10.1111/aas.14124.
• Trøseid, Marius; Hites, Maya; Barratt-Due, Andreas; Ader, Florence & Yazdanpanah, Yazdan (2021). Assessing the evidence on remdesivir. The Lancet Infectious Diseases. ISSN 1473-3099. 21(12), p. 1630–1631. doi: 10.1016/S1473-3099(21)00695-2.
• Blaise Pascal, Furaha Nzanzu; Malisawa, Agnes; Barratt-Due, Andreas; Namboya, Felix & Pollach, Gregor (2021). Correction to: General anaesthesia related mortality in a limited resource settings region: a retrospective study in two teaching hospitals of Butembo (BMC Anesthesiology, (2021), 21, 1, (60), 10.1186/s12871-021-01280-2). BMC Anesthesiology. ISSN 1471-2253. 21(1). doi: 10.1186/s12871-021-01297-7.
• Azoulay, Elie; Bauer, Philippe R.; Mariotte, Eric; Russell, Lene; Knoebl, Paul & Martin-Loeches, Ignacio [Show all 20 contributors for this article] (2020). Correction to: Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura (Intensive Care Medicine, (2019), 45, 11, (1518-1539), 10.1007/s00134-019-05736-5). Intensive Care Medicine. ISSN 0342-4642. 46(3), p. 570–571. doi: 10.1007/s00134-019-05904-7.
• Martin-Loeches, Ignacio; Darmon, Michael; Demoule, Alexandre; Antonelli, Massimo; Schellongowski, Peter & Pickkers, Peter [Show all 23 contributors for this article] (2020). ICU-acquired pneumonia in immunosuppressed patients with acute hypoxemic respiratory failure: A post-hoc analysis of a prospective international cohort study. Journal of critical care. ISSN 0883-9441. p. 1–3. doi: 10.1016/j.jcrc.2020.09.027.
• Laake, Jon Henrik; Aasmundstad, Tor Aksel; Kåsine, Trine; Pischke, Soeren & Barratt-Due, Andreas (2020). Covid-19: Evidens-, eminens-, eller erfaringsbasert behandling? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 140(12), p. 1–2. doi: 10.4045/tidsskr.20.0649.
• Laffey, John G.; Bellani, Giacomo; Pham, Tài; Fan, Eddy; Madotto, Fabiana & Bajwa, Ednan K. [Show all 30 contributors for this article] (2018). Correction to: Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study (Intensive Care Medicine, (2016), 42, 12, (1865-1876), 10.1007/s00134-016-4571-5). Intensive Care Medicine. ISSN 0342-4642. 44(1), p. 157–165. doi: 10.1007/s00134-017-4981-z.
• Buanes, Eirik Alnes; Barratt-Due, Andreas; Kvåle, Reidar; Leistad, Lillian & Konstante, Rita (2018). Viktig å skilje intermediærpasientar frå intensivpasientar. Tidsskrift for Den norske legeforening. ISSN 0029-2001.
• Buanes, Eirik Alnes; Barratt-Due, Andreas; Leistad, Lillian & Konstante, Rita (2018). Viktig å skilje intermediærpasientar frå intensivpasientar. Tidsskrift for Den norske legeforening. ISSN 0029-2001.
• Mollnes, Tom Eirik; Barratt-Due, Andreas; Pischke, Søren Erik; Sandanger, Inger; Nilsson, Per & Lambris, J [Show all 10 contributors for this article] (2013). Double-blockade of CD14 and complement component C5 abolish the inflammatory storm and improve survival in mouse polymicrobial sepsis. Molecular Immunology. ISSN 0161-5890. 56(3), p. 294–294. doi: 10.1016/j.molimm.2013.05.153.
• Egge, Kjetil Hagene; Thorgersen, Ebbe Billmann; Lindstad, Julie Katrine; Pharo, Anne Margrethe; Bongoni, AK & Rieben, R [Show all 8 contributors for this article] (2013). Combined inhibition of C5 and CD14 attenuates organ inflammation in porcine Escherichia coli sepsis. Molecular Immunology. ISSN 0161-5890. 56(3), p. 246–246. doi: 10.1016/j.molimm.2013.05.027.
• Egge, Kjetil Hagene; Thorgersen, Ebbe Billmann; Lindstad, Julie Katrine; Pharo, Anne Margrethe; Lambris, J.D. & Barratt-Due, Andreas [Show all 7 contributors for this article] (2013). Combined inhibition of C3 and CD14 attenuates the inflammatory reaction significantly more as compared to single inhibition. Molecular Immunology. ISSN 0161-5890. 56(3), p. 304–305. doi: 10.1016/j.molimm.2013.05.182.
• Egge, Kjetil Hagene; Thorgersen, Ebbe Billmann; Lindstad, Julie Katrine; Pharo, Anne Margrethe; Barratt-Due, Andreas & Mollnes, Tom Eirik (2012). An ex vivo posttreatment model of sepsis: Effect on inflammation by adding complement- and CD14-inhibitors after E. coli to human whole blood. Immunobiology. ISSN 0171-2985. 217(11), p. 1137–1138. doi: 10.1016/j.imbio.2012.08.026.
• Mollnes, Tom Eirik; Barratt-Due, Andreas; Pischke, Søren Erik; Sandanger, Øystein; Nunn, Miles A. & Espevik, Terje [Show all 8 contributors for this article] (2012). The systemic inflammatory reaction in polymicrobial sepsis induced by murine cecal ligation and puncture is equally dependent on C5 and CD14. Immunobiology. ISSN 0171-2985. 217(11), p. 1129–1129. doi: 10.1016/j.imbio.2012.08.002.
• Thorgersen, Ebbe Billmann; Pischke, Søren Erik; Barratt-Due, Andreas; Fure, Hilde; Lindstad, Julie Katrine & Pharo, Anne Margrethe [Show all 8 contributors for this article] (2012). Systemic CD14-inhibition attenuates local inflammatory responses organ-dependently in porcine Escherichia coli-sepsis. Immunobiology. ISSN 0171-2985. 217(11), p. 1206–1206. doi: 10.1016/j.imbio.2012.08.222.
• Barratt-Due, Andreas; Thorgersen, Ebbe Billmann; Lindstad, Julie Katrine; Pharo, Anne Margrethe; Nunn, Miles A. & Mollnes, Tom Eirik (2010). Ornithodoros moubata complement inhibitor (OmCI)-A novel and efficient C5 inhibitor in the pig. Molecular Immunology. ISSN 0161-5890. 47(13), p. 2205–2205. doi: 10.1016/j.molimm.2010.05.033.
• Thorgersen, Ebbe Billmann; Hellerud, Bernt C; Nielsen, Erik Waage; Barratt-Due, Andreas; Fure, Hilde & Lindstad, Julie Katrine [Show all 12 contributors for this article] (2010). Upstream inhibition of key innate immune pathways in vivo in sepsis. Molecular Immunology. ISSN 0161-5890. 47(13), p. 2268–2268. doi: 10.1016/j.molimm.2010.05.209.

View all works in Cristin